Roche drops out of dev deal with Maxygen

Roche is dropping out of its partnership with Maxygen to develop a therapy for uncontrolled bleeding in an emergency setting. The company expressed its disappointment at the decision, but added that the two drug companies would continue to work together on programs for hepatitis C and B.

- read this press release
- check out the AP report on the undoing of the deal

Suggested Articles

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.